Analgesics in Singapore

Abstract
Following the commencement of nationwide vaccination across all ages in late December 2020, residents in Singapore have responded positively to related public health campaigns, with a fully vaccinated rate of 87.8% as of April 2022. The use of over-the-counter systemic analgesics to cope with post-vaccination fever and other uncomfortable conditions was recommended by the local government and medical doctors. In particular, leading brand Panadol was recommended as an effective analgesic and anti...

Euromonitor International's Analgesics in Singapore report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2017-2021, allowing you to identify the sectors driving growth. Forecasts to 2026 illustrate how the market is set to change.

Product coverage: Systemic Analgesics, Topical Analgesics/Anaesthetic.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
* Get a detailed picture of the Analgesics market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.

Content
Analgesics in Singapore

List Of Contents And Tables

ANALGESICS IN SINGAPORE
KEY DATA FINDINGS
2022 DEVELOPMENTS
Systemic analgesics experiences surge in demand with rise in local vaccination rates and evolving nature of COVID-19
Milder decline in use of non-steroidal anti-inflammatory systemic analgesics due to local health needs
Evolving demographic needs drive demand for topical analgesics/anaesthetic
PROSPECTS AND OPPORTUNITIES
Easing of travel restrictions to promote overall category growth
Rise in travel to drive recovery of herbal/traditional topical analgesics
Systemic analgesics likely to experience slowing demand due to high local vaccination rates
CATEGORY DATA
Table 1 Sales of Analgesics by Category: Value 2017-2022
Table 2 Sales of Analgesics by Category: % Value Growth 2017-2022
Table 3 NBO Company Shares of Analgesics: % Value 2018-2022
Table 4 LBN Brand Shares of Analgesics: % Value 2019-2022
Table 5 Forecast Sales of Analgesics by Category: Value 2022-2027
Table 6 Forecast Sales of Analgesics by Category: % Value Growth 2022-2027
CONSUMER HEALTH IN SINGAPORE
EXECUTIVE SUMMARY
Consumer health in 2022: The big picture
2022 key trends
Competitive landscape
Retailing developments
What next for consumer health?
MARKET INDICATORS
Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2017-2022
Table 8 Life Expectancy at Birth 2017-2022
MARKET DATA
Table 9 Sales of Consumer Health by Category: Value 2017-2022
Table 10 Sales of Consumer Health by Category: % Value Growth 2017-2022
Table 11 NBO Company Shares of Consumer Health: % Value 2018-2022
Table 12 LBN Brand Shares of Consumer Health: % Value 2019-2022
Table 13 Penetration of Private Label in Consumer Health by Category: % Value 2017-2022
Table 14 Distribution of Consumer Health by Format: % Value 2017-2022
Table 15 Distribution of Consumer Health by Format and Category: % Value 2022
Table 16 Forecast Sales of Consumer Health by Category: Value 2022-2027
Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2022-2027
APPENDIX
OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
DISCLAIMER
DEFINITIONS
SOURCES
Summary 1 Research Sources